HDFC Bank, India Cements and Ircon International to see some action today

HDFC Bank has reported results for second quarter ended September 30, 2025 (Q2FY26). The Bank has reported 10.82% rise in its net profit at Rs 18,641.28 crore for the second quarter ended September 30, 2025 as compared to Rs 16,820.97 crore for the same quarter in the previous year. Total income of the Bank increased by 6.48% at Rs 91,040.72 crore for Q2FY26 as compared to Rs 85,499.64 crore for the corresponding quarter previous year. On consolidated basis, the bank has reported 10.01% rise in its net profit at Rs 19,610.67 crore for Q2FY26 as compared to Rs 17,825.91 crore for the same quarter in the previous year. However, the total income of the bank decreased by 2.38% at Rs 1,18,560.63 crore for Q2FY26 as compared to Rs 1,21,456.74 crore for the corresponding quarter previous year.

The India Cements has received approval for capex towards capacity expansion and modernisation. The company’s board has approved an investment of Rs 440 crore for capacity expansion, under which the company will add a capacity of 2.80 million tonnes to its existing capacity 14.75 million tonnes, which is currently operating at a capacity utilization of 60% to 75%. The new capacity will be added in around 2 years. In addition to capacity expansion, the board of directors approved an investment of Rs 1,574 crore towards modernization. The Board of Directors of the company at their meeting held on October 17, 2025, approved the same.

Ircon International has secured work order worth around Rs 360. 28 crore (excluding 18% GST) from Petronet LNG. The work order is for civil, structural & UG works including piling - PART-A' for PDH-PP Plant with Ethane and Propane Storage and Handling Facilities at Dahej, Gujarat. The order is to be executed within 18 months.

R.P.P. Infra Projects has secured letter of acceptance for new work order for provision of civil works for construction of office cum training Building and Residential Accommodation for officers and staff of national academy of defence financial Management (NADFM) Pune. The company has secured the order from Chief Construction Engineer (R&D)W  Pune. The order is valued at Rs 125.92 crore and to be executed within 36 months.

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Triamcinolone Acetonide Injectable Suspension USP, 40 mg/mL Single-Dose Vials, 200 mg/5 mL and 400 mg/10 mL (40 mg/mL) Multiple-Dose Vials. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Kenalog-40 Injectable Suspension, of BristolMyers Squibb Company. The company has a cumulative total of 227 ANDA approvals (206 final approvals and 21 tentative approvals) from USFDA. Triamcinolone Acetonide Injectable Suspension USP is indicated for various autoimmune, inflammatory, and other conditions where oral therapy is not feasible.

Pidilite Industries’ wholly owned subsidiary -- Pidilite Ventures has invested upto Rs 34 crore in Imagimake Play Solutions (Imagimake). Imagimake is an innovation-led company designing and distributing educational toys, games, and art & hobby products. This Series B round comprises a mix of primary and secondary capital. The investment from this round will enable Imagimake to accelerate capacity expansion, strengthen R&D, and scale its global distribution network.

Rail Vikas Nigam has emerged as the Lowest Bidder (L1) in reverse auction from South Central Railway. The auction was for the contract of design, supply, erection, testing and commissioning for OHE up gradation of existing 1X25kV system to 2X25kV AT feeding system with feeder and earthing works in Ramgundam (RDM) - Kazipet (KZJ) section of Secunderabad Division under South Central Railway, Total 92 RKM/ 276 TKM. The contract is valued at around Rs 144.44 crore (including applicable taxes). The contract is to be executed within 18 months.